Small Molecules

22 Sep 2017 Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist
22 Sep 2017 Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
22 Sep 2017 New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial
21 Sep 2017 FLX Bio Selects Immuno-Oncology Clinical Candidate
21 Sep 2017 BioCryst's RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication
21 Sep 2017 PharmaMar starts clinical studies with a new compound –PM14- in patients with solid tumors
21 Sep 2017 KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
21 Sep 2017 Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor
20 Sep 2017 Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
20 Sep 2017 Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial
20 Sep 2017 Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
20 Sep 2017 GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations
20 Sep 2017 Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
19 Sep 2017 Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis
19 Sep 2017 Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
19 Sep 2017 Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
19 Sep 2017 MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
19 Sep 2017 Supernus Provides Update on SPN-810 Phase III Clinical Trials
19 Sep 2017 Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
19 Sep 2017 Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting
19 Sep 2017 Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
19 Sep 2017 Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
19 Sep 2017 Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
18 Sep 2017 AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
18 Sep 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top